Medical Consortium for Screening Upper Gastrointestinal Cancers With Magnetically Controlled Capsule Gastroscopy

Not Applicable

• Conditions: Capsule Endoscopy; Cancer of Stomach; Cancer of Esophagus; Health Policy

• Registration Number: NCT04032353
• Lead Sponsor: Yanqing Li

Brief Summary

The aim of our study was to demonstrate the efficacy and feasibility of the medical consortium for screening upper gastrointestinal cancers with magnetically controlled capsule gastroscopy.

Detailed Description

In this study, the investigators designed a propective cohort study to evaluate the the efficacy and feasibility of medical consortium for screening upper gastrointestinal cancers (MCSC) with magnetically controlled capsule gastroscopy (MCCG).

Study Timeline

• Study Start: 2018-12-31
• Status Verified: 2019-07
• Study First Submitted: 2019-07-23
• Study First Submitted QC: 2019-07-24
• Last Update Submitted: 2019-07-24
• Study First Posted: 2019-07-25
• Last Update Posted: 2019-07-25
• Primary Completion: 2019-12-31
• Study Completion: 2020-03-01

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 10000

Inclusion Criteria

• asymptomatic subjects undergong magnetically controlled capsule gastroscopy for health checkup in medical consotium;
• subjects able to give informed consent

Exclusion Criteria

• suspected or known intestinal stenosis, obstruction, or fistula;
• inoperability of refusal to accept any abdominal surgery;
• dysphagia or gastric paralysis;
• previous history of gastrointestinal disease;
• with pacemaker, implanted-cardiac defibrillator or other implanted electromedical devices;
• need for standard magnetic resonance imaging examination within seven days after swallowing the MCCG, unless the capsule is confirmed to have been excreted;
• other factors that are not suitable for inclusion evaluated by medical stuff

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
the incidence of upper gastrointestinal cancers, including gastric cancer and esophageal cancer.	12 months

Secondary Outcome Measures

Name	Time	Method
tthe focal lesions of upper gastrointestinal tract	12 months

Trial Locations

Locations (1)

Department of Gastroenterology, Qilu Hospital, Shandong University; 🇨🇳 Jinan, Shandong, China